Top

Published in:

Open Access 01-06-2019 | Breast Cancer | Review

Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions

Authors: Adriana C. Rodriguez, Zannel Blanchard, Kathryn A. Maurer, Jason Gertz

Published in: Discover Oncology | Issue 2-3/2019

Abstract

Endometrial cancer is the most common gynecological cancer in the developed world, and it is one of the few cancer types that is becoming more prevalent and leading to more deaths in the USA each year. The majority of endometrial tumors are considered to be hormonally driven, where estrogen signaling through estrogen receptor α (ER) acts as an oncogenic signal. The major risk factors and some treatment options for endometrial cancer patients emphasize a key role for estrogen signaling in the disease. Despite the strong connections between estrogen signaling and endometrial cancer, important molecular aspects of ER function remain poorly understood; however, progress is being made in our understanding of estrogen signaling in endometrial cancer. Here, we discuss the evidence for the importance of estrogen signaling in endometrial cancer, details of the endometrial cancer-specific actions of ER, and open questions surrounding estrogen signaling in endometrial cancer.

SEER Cancer Stat Facts: Uterine cancer. National Cancer Institute Bethesda M, https://seer.cancer.gov/statfacts/html/corp.html. Accessed Oct 2018

Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15(1):10–17CrossRefPubMed

Carlson MJ, Thiel KW, Leslie KK (2014) Past, present, and future of hormonal therapy in recurrent endometrial cancer. Int J Women's Health 6:429–435. https://doi.org/10.2147/IJWH.S40942 CrossRef

Jongen V, Briet J, de Jong R, ten Hoor K, Boezen M, van der Zee A, Nijman H, Hollema H (2009) Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol 112(3):537–542. https://doi.org/10.1016/j.ygyno.2008.10.032 CrossRefPubMed

Shen F, Gao Y, Ding J, Chen Q (2017) Is the positivity of estrogen receptor or progesterone receptor different between type 1 and type 2 endometrial cancer? Oncotarget 8(1):506–511. https://doi.org/10.18632/oncotarget.13471 CrossRefPubMed

Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, Mestdagh P, Gunaratne PH, Yau C, Bowlby R, Robertson AG, Tiezzi DG, Wang C, Cherniack AD, Godwin AK, Kuderer NM, Rader JS, Zuna RE, Sood AK, Lazar AJ, Ojesina AI, Adebamowo C, Adebamowo SN, Baggerly KA, Chen TW, Chiu HS, Lefever S, Liu L, MacKenzie K, Orsulic S, Roszik J, Shelley CS, Song Q, Vellano CP, Wentzensen N, Weinstein JN, Mills GB, Levine DA, Akbani R, Cancer Genome Atlas Research N (2018) A comprehensive pan-cancer molecular study of gynecologic and breast cancers. Cancer Cell 33(4):690–705 e9. https://doi.org/10.1016/j.ccell.2018.03.014 CrossRefPubMedPubMedCentral

Setiawan VW, Yang HP, Pike MC, SE MC, Yu H, Xiang YB, Wolk A, Wentzensen N, Weiss NS, Webb PM, van den Brandt PA, van de Vijver K, Thompson PJ, Strom BL, Spurdle AB, Soslow RA, Shu XO, Schairer C, Sacerdote C, Rohan TE, Robien K, Risch HA, Ricceri F, Rebbeck TR, Rastogi R, Prescott J, Polidoro S, Park Y, Olson SH, Moysich KB, Miller AB, ML MC, Matsuno RK, Magliocco AM, Lurie G, Lu L, Lissowska J, Liang X, Lacey JV Jr, Kolonel LN, Henderson BE, Hankinson SE, Hakansson N, Goodman MT, Gaudet MM, Garcia-Closas M, Friedenreich CM, Freudenheim JL, Doherty J, De Vivo I, Courneya KS, Cook LS, Chen C, Cerhan JR, Cai H, Brinton LA, Bernstein L, Anderson KE, Anton-Culver H, Schouten LJ, Horn-Ross PL, Australian National Endometrial Cancer Study G (2013) Type I and II endometrial cancers: have they different risk factors? J Clin Oncol : Official Journal of the American Society of Clinical Oncology 31(20):2607–2618. https://doi.org/10.1200/JCO.2012.48.2596 CrossRef

Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA, Cancer Genome Atlas Research N (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497(7447):67–73. https://doi.org/10.1038/nature12113 CrossRefPubMed

Groothuis PG, Dassen HH, Romano A, Punyadeera C (2007) Estrogen and the endometrium: lessons learned from gene expression profiling in rodents and human. Hum Reprod Update 13(4):405–417. https://doi.org/10.1093/humupd/dmm009 CrossRefPubMed

10.

Reed BG, Carr BR (2000) The normal menstrual cycle and the control of ovulation. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A (eds) Endotext. MDText.com, Inc., South Dartmouth

11.

Mesen TB, Young SL (2015) Progesterone and the luteal phase: a requisite to reproduction. Obstet Gynecol Clin N Am 42(1):135–151. https://doi.org/10.1016/j.ogc.2014.10.003 CrossRef

12.

Erdemoglu E, Guney M, Giray SG, Take G, Mungan T (2009) Effects of metformin on mammalian target of rapamycin in a mouse model of endometrial hyperplasia. Eur J Obstet Gynecol Reprod Biol 145(2):195–199. https://doi.org/10.1016/j.ejogrb.2009.04.034 CrossRefPubMed

13.

Newbold RR, Bullock BC, McLachlan JA (1990) Uterine adenocarcinoma in mice following developmental treatment with estrogens: a model for hormonal carcinogenesis. Cancer Res 50(23):7677–7681PubMed

14.

Vollmer G (2003) Endometrial cancer: experimental models useful for studies on molecular aspects of endometrial cancer and carcinogenesis. Endocr Relat Cancer 10(1):23–42CrossRefPubMed

15.

Yang CH, Almomen A, Wee YS, Jarboe EA, Peterson CM, Janat-Amsbury MM (2015) An estrogen-induced endometrial hyperplasia mouse model recapitulating human disease progression and genetic aberrations. Cancer Med 4(7):1039–1050. https://doi.org/10.1002/cam4.445 CrossRefPubMedPubMedCentral

16.

Dobbins M, Decorby K, Choi BC (2013) The association between obesity and cancer risk: a meta-analysis of observational studies from 1985 to 2011. ISRN Prev Med 2013:680536. https://doi.org/10.5402/2013/680536 CrossRefPubMedPubMedCentral

17.

Raglan O, Kalliala I, Markozannes G, Cividini S, Gunter MJ, Nautiyal J, Gabra H, Paraskevaidis E, Martin-Hirsch P, Tsilidis KK, Kyrgiou M (2018) Risk factors for endometrial cancer: an umbrella review of the literature. Int J Cancer. https://doi.org/10.1002/ijc.31961

18.

Hemsell DL, Grodin JM, Brenner PF, Siiteri PK, MacDonald PC (1974) Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. J Clin Endocrinol Metab 38(3):476–479. https://doi.org/10.1210/jcem-38-3-476 CrossRefPubMed

19.

Cleland WH, Mendelson CR, Simpson ER (1983) Aromatase activity of membrane fractions of human adipose tissue stromal cells and adipocytes. Endocrinology 113(6):2155–2160. https://doi.org/10.1210/endo-113-6-2155 CrossRefPubMed

20.

Santen RJ, Brodie H, Simpson ER, Siiteri PK, Brodie A (2009) History of aromatase: saga of an important biological mediator and therapeutic target. Endocr Rev 30(4):343–375. https://doi.org/10.1210/er.2008-0016 CrossRefPubMed

21.

Giviziez CR, Sanchez EG, Approbato MS, Maia MC, Fleury EA, Sasaki RS (2016) Obesity and anovulatory infertility: a review. JBRA Assist Reprod 20(4):240–245. https://doi.org/10.5935/1518-0557.20160046 CrossRefPubMedPubMedCentral

22.

Rich-Edwards JW, Spiegelman D, Garland M, Hertzmark E, Hunter DJ, Colditz GA, Willett WC, Wand H, Manson JE (2002) Physical activity, body mass index, and ovulatory disorder infertility. Epidemiology 13(2):184–190CrossRefPubMed

23.

Silvestris E, de Pergola G, Rosania R, Loverro G (2018) Obesity as disruptor of the female fertility. Reprod Biol Endocrinol 16(1):22. https://doi.org/10.1186/s12958-018-0336-z CrossRefPubMedPubMedCentral

24.

Kurita T, Young P, Brody JR, Lydon JP, O'Malley BW, Cunha GR (1998) Stromal progesterone receptors mediate the inhibitory effects of progesterone on estrogen-induced uterine epithelial cell deoxyribonucleic acid synthesis. Endocrinology 139(11):4708–4713. https://doi.org/10.1210/endo.139.11.6317 CrossRefPubMed

25.

Daniilidis A, Dinas K (2009) Long term health consequences of polycystic ovarian syndrome: a review analysis. Hippokratia 13(2):90–92PubMedPubMedCentral

26.

Deng Y, Zhang Y, Li S, Zhou W, Ye L, Wang L, Tao T, Gu J, Yang Z, Zhao D, Gu W, Hong J, Ning G, Liu W, Wang W (2017) Steroid hormone profiling in obese and nonobese women with polycystic ovary syndrome. Sci Rep 7(1):14156. https://doi.org/10.1038/s41598-017-14534-2 CrossRefPubMedPubMedCentral

27.

Antunes CM, Strolley PD, Rosenshein NB, Davies JL, Tonascia JA, Brown C, Burnett L, Rutledge A, Pokempner M, Garcia R (1979) Endometrial cancer and estrogen use. Report of a large case-control study. N Engl J Med 300(1):9–13. https://doi.org/10.1056/NEJM197901043000103 CrossRefPubMed

28.

Meyer LA, Broaddus RR, Lu KH (2009) Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control 16(1):14–22. https://doi.org/10.1177/107327480901600103 CrossRefPubMed

29.

Gammon A, Jasperson K, Champine M (2016) Genetic basis of Cowden syndrome and its implications for clinical practice and risk management. Appl Clin Genet 9:83–92. https://doi.org/10.2147/TACG.S41947 CrossRefPubMedPubMedCentral

30.

Denschlag D, Ulrich U, Emons G (2010) The diagnosis and treatment of endometrial cancer: progress and controversies. Dtsch Arztebl Int 108(34–35):571–577. https://doi.org/10.3238/arztebl.2011.0571 CrossRefPubMed

31.

Dinkelspiel HE, Wright JD, Lewin SN, Herzog TJ (2013) Contemporary clinical management of endometrial cancer. Obstet Gynecol Int 2013:583891. https://doi.org/10.1155/2013/583891 CrossRefPubMedPubMedCentral

32.

Carroll JS, Hickey TE, Tarulli GA, Williams M, Tilley WD (2017) Deciphering the divergent roles of progestogens in breast cancer. Nat Rev Cancer 17(1):54–64. https://doi.org/10.1038/nrc.2016.116 CrossRefPubMed

33.

Gallos ID, Yap J, Rajkhowa M, Luesley DM, Coomarasamy A, Gupta JK (2012) Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 207(4):266 e1–12. https://doi.org/10.1016/j.ajog.2012.08.011 CrossRefPubMed

34.

Baker J, Obermair A, Gebski V, Janda M (2012) Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecol Oncol 125(1):263–270. https://doi.org/10.1016/j.ygyno.2011.11.043 CrossRefPubMed

35.

Gien L, Kwon J, Oliver TK, Fung-Kee-Fung M (2008) Adjuvant hormonal therapy for stage I endometrial cancer. Curr Oncol 15(3):126–135PubMedPubMedCentral

36.

Jordan VC (2014) Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer. Endocr Relat Cancer 21(3):R235–R246. https://doi.org/10.1530/ERC-14-0092 CrossRefPubMedPubMedCentral

37.

Tremont A, Lu J, Cole JT (2017) Endocrine therapy for early breast cancer: updated review. Ochsner J 17(4):405–411PubMedPubMedCentral

38.

Bartosch C, Monteiro-Reis S, Vieira R, Pereira A, Rodrigues M, Jeronimo C, Lopes JM (2015) Endometrial endometrioid carcinoma metastases show decreased ER-alpha and PR-A expression compared to matched primary tumors. PLoS One 10(8):e0134969. https://doi.org/10.1371/journal.pone.0134969 CrossRefPubMedPubMedCentral

39.

Battista MJ, Schmidt M (2016) Fulvestrant for the treatment of endometrial cancer. Expert Opin Investig Drugs 25(4):475–483. https://doi.org/10.1517/13543784.2016.1154532 CrossRefPubMed

40.

Asbury RF, Brunetto VL, Lee RB, Reid G, Rocereto TF, Gynecologic OG (2002) Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Am J Clin Oncol 25(6):557–560CrossRefPubMed

41.

Fiorica JV, Brunetto VL, Hanjani P, Lentz SS, Mannel R, Andersen W, Gynecologic Oncology Groups (2004) Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92(1):10–14CrossRefPubMed

42.

Lentz SS, Brady MF, Major FJ, Reid GC, Soper JT (1996) High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 14(2):357–361. https://doi.org/10.1200/JCO.1996.14.2.357 CrossRef

43.

McMeekin DS, Gordon A, Fowler J, Melemed A, Buller R, Burke T, Bloss J, Sabbatini P (2003) A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. Gynecol Oncol 90(1):64–69CrossRefPubMed

44.

Pandya KJ, Yeap BY, Weiner LM, Krook JE, Erban JK, Schinella RA, Davis TE (2001) Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group Study (E4882). Am J Clin Oncol 24(1):43–46CrossRefPubMed

45.

Piver MS, Barlow JJ, Lurain JR, Blumenson LE (1980) Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma. Cancer 45(2):268–272CrossRefPubMed

46.

Podratz KC, O'Brien PC, Malkasian GD Jr, Decker DG, Jefferies JA, Edmonson JH (1985) Effects of progestational agents in treatment of endometrial carcinoma. Obstet Gynecol 66(1):106–110PubMed

47.

Rose PG, Brunetto VL, VanLe L, Bell J, Walker JL, Lee RB (2000) A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 78(2):212–216. https://doi.org/10.1006/gyno.2000.5865 CrossRefPubMed

48.

Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HD, Manetta A, Soper JT, Given FT (1999) Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol : Official Journal of the American Society of Clinical Oncology 17(6):1736–1744. https://doi.org/10.1200/JCO.1999.17.6.1736 CrossRef

49.

Thigpen T, Brady MF, Homesley HD, Soper JT, Bell J (2001) Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol : Official Journal of the American Society of Clinical Oncology 19(2):364–367. https://doi.org/10.1200/JCO.2001.19.2.364 CrossRef

50.

Whitney CW, Brunetto VL, Zaino RJ, Lentz SS, Sorosky J, Armstrong DK, Lee RB, Gynecologic Oncology Groups (2004) Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92(1):4–9CrossRefPubMed

51.

Battista MJ, Schmidt M, Eichbaum M, Almstedt K, Heimes AS, Mallmann P, Hoffmann G, Steiner E (2015) Management of recurrent or metastatic endometrial cancer in Germany: results of the nationwide AGO pattern of care studies from the years 2013, 2009 and 2006. Arch Gynecol Obstet 292(6):1355–1360. https://doi.org/10.1007/s00404-015-3786-y CrossRefPubMed

52.

Lee WL, Yen MS, Chao KC, Yuan CC, Ng HT, Chao HT, Lee FK, Wang PH (2014) Hormone therapy for patients with advanced or recurrent endometrial cancer. J Chin Med Assoc 77(5):221–226. https://doi.org/10.1016/j.jcma.2014.02.007 CrossRefPubMed

53.

Temkin SM, Fleming G (2009) Current treatment of metastatic endometrial cancer. Cancer Control 16(1):38–45CrossRefPubMed

54.

Fannon SA, Vidaver RM, Marts SA (2001) An abridged history of sex steroid hormone receptor action. J Appl Physiol (1985) 91(4):1854–1859. https://doi.org/10.1152/jappl.2001.91.4.1854 CrossRef

55.

Walter P, Green S, Greene G, Krust A, Bornert JM, Jeltsch JM, Staub A, Jensen E, Scrace G, Waterfield M et al (1985) Cloning of the human estrogen receptor cDNA. Proc Natl Acad Sci U S A 82(23):7889–7893CrossRefPubMedPubMedCentral

56.

Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA (1996) Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 93(12):5925–5930CrossRefPubMedPubMedCentral

57.

Yi P, Wang Z, Feng Q, Pintilie GD, Foulds CE, Lanz RB, Ludtke SJ, Schmid MF, Chiu W, O'Malley BW (2015) Structure of a biologically active estrogen receptor-coactivator complex on DNA. Mol Cell 57(6):1047–1058. https://doi.org/10.1016/j.molcel.2015.01.025 CrossRefPubMedPubMedCentral

58.

Schwabe JW, Chapman L, Finch JT, Rhodes D (1993) The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: how receptors discriminate between their response elements. Cell 75(3):567–578CrossRefPubMed

59.

Zwart W, de Leeuw R, Rondaij M, Neefjes J, Mancini MA, Michalides R (2010) The hinge region of the human estrogen receptor determines functional synergy between AF-1 and AF-2 in the quantitative response to estradiol and tamoxifen. J Cell Sci 123(Pt 8):1253–1261. https://doi.org/10.1242/jcs.061135 CrossRefPubMed

60.

Tanenbaum DM, Wang Y, Williams SP, Sigler PB (1998) Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc Natl Acad Sci U S A 95(11):5998–6003CrossRefPubMedPubMedCentral

61.

Danielian PS, White R, Lees JA, Parker MG (1992) Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J 11(3):1025–1033CrossRefPubMedPubMedCentral

62.

Hewitt SC, Korach KS (2002) Estrogen receptors: structure, mechanisms and function. Rev Endocr Metab Disord 3(3):193–200CrossRefPubMed

63.

Hapangama DK, Kamal AM, Bulmer JN (2015) Estrogen receptor beta: the guardian of the endometrium. Hum Reprod Update 21(2):174–193. https://doi.org/10.1093/humupd/dmu053 CrossRefPubMed

64.

Carmeci C, Thompson DA, Ring HZ, Francke U, Weigel RJ (1997) Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics 45(3):607–617. https://doi.org/10.1006/geno.1997.4972 CrossRefPubMed

65.

Owman C, Blay P, Nilsson C, Lolait SJ (1996) Cloning of human cDNA encoding a novel heptahelix receptor expressed in Burkitt's lymphoma and widely distributed in brain and peripheral tissues. Biochem Biophys Res Commun 228(2):285–292. https://doi.org/10.1006/bbrc.1996.1654 CrossRefPubMed

66.

Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER (2005) A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307(5715):1625–1630. https://doi.org/10.1126/science.1106943 CrossRefPubMed

67.

Thomas P, Pang Y, Filardo EJ, Dong J (2005) Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 146(2):624–632. https://doi.org/10.1210/en.2004-1064 CrossRefPubMed

68.

Skrzypczak M, Schuler S, Lattrich C, Ignatov A, Ortmann O, Treeck O (2013) G protein-coupled estrogen receptor (GPER) expression in endometrial adenocarcinoma and effect of agonist G-1 on growth of endometrial adenocarcinoma cell lines. Steroids 78(11):1087–1091. https://doi.org/10.1016/j.steroids.2013.07.007 CrossRefPubMed

69.

Losel R, Wehling M (2003) Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol 4(1):46–56. https://doi.org/10.1038/nrm1009 CrossRefPubMed

70.

Pietras RJ, Szego CM (1977) Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature 265(5589):69–72CrossRefPubMed

71.

Kahlert S, Nuedling S, van Eickels M, Vetter H, Meyer R, Grohe C (2000) Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J Biol Chem 275(24):18447–18453. https://doi.org/10.1074/jbc.M910345199

72.

Ui H, Mueller GC (1963) The role of RNA synthesis in early estrogen action. Proc Natl Acad Sci U S A 50:256–260CrossRefPubMedPubMedCentral

73.

Kumar V, Chambon P (1988) The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 55(1):145–156CrossRefPubMed

74.

Klein-Hitpass L, Schorpp M, Wagner U, Ryffel GU (1986) An estrogen-responsive element derived from the 5′ flanking region of the Xenopus vitellogenin A2 gene functions in transfected human cells. Cell 46(7):1053–1061CrossRefPubMed

75.

Walker P, Germond JE, Brown-Luedi M, Givel F, Wahli W (1984) Sequence homologies in the region preceding the transcription initiation site of the liver estrogen-responsive vitellogenin and apo-VLDLII genes. Nucleic Acids Res 12(22):8611–8626CrossRefPubMedPubMedCentral

76.

Welboren WJ, van Driel MA, Janssen-Megens EM, van Heeringen SJ, Sweep FC, Span PN, Stunnenberg HG (2009) ChIP-Seq of ERalpha and RNA polymerase II defines genes differentially responding to ligands. EMBO J 28(10):1418–1428. https://doi.org/10.1038/emboj.2009.88 CrossRefPubMedPubMedCentral

77.

Joseph R, Orlov YL, Huss M, Sun W, Kong SL, Ukil L, Pan YF, Li G, Lim M, Thomsen JS, Ruan Y, Clarke ND, Prabhakar S, Cheung E, Liu ET (2010) Integrative model of genomic factors for determining binding site selection by estrogen receptor-alpha. Mol Syst Biol 6:456. https://doi.org/10.1038/msb.2010.109 CrossRefPubMedPubMedCentral

78.

Gertz J, Savic D, Varley KE, Partridge EC, Safi A, Jain P, Cooper GM, Reddy TE, Crawford GE, Myers RM (2013) Distinct properties of cell-type-specific and shared transcription factor binding sites. Mol Cell 52(1):25–36. https://doi.org/10.1016/j.molcel.2013.08.037 CrossRefPubMed

79.

Krishnan V, Wang X, Safe S (1994) Estrogen receptor-Sp1 complexes mediate estrogen-induced cathepsin D gene expression in MCF-7 human breast cancer cells. J Biol Chem 269(22):15912–15917PubMed

80.

Safe S, Kim K (2008) Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways. J Mol Endocrinol 41(5):263–275. https://doi.org/10.1677/JME-08-0103 CrossRefPubMedPubMedCentral

81.

Heldring N, Isaacs GD, Diehl AG, Sun M, Cheung E, Ranish JA, Kraus WL (2011) Multiple sequence-specific DNA-binding proteins mediate estrogen receptor signaling through a tethering pathway. Mol Endocrinol 25(4):564–574. https://doi.org/10.1210/me.2010-0425 CrossRefPubMedPubMedCentral

82.

Gertz J, Reddy TE, Varley KE, Garabedian MJ, Myers RM (2012) Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res 22(11):2153–2162. https://doi.org/10.1101/gr.135681.111 CrossRefPubMedPubMedCentral

83.

Droog M, Nevedomskaya E, Kim Y, Severson T, Flach KD, Opdam M, Schuurman K, Gradowska P, Hauptmann M, Dackus G, Hollema H, Mourits M, Nederlof P, van Boven H, Linn SC, Wessels L, van Leeuwen FE, Zwart W (2016) Comparative cistromics reveals genomic cross-talk between FOXA1 and ERalpha in tamoxifen-associated endometrial carcinomas. Cancer Res 76(13):3773–3784. https://doi.org/10.1158/0008-5472.CAN-14-1813 CrossRefPubMed

84.

He HH, Meyer CA, Chen MW, Jordan VC, Brown M, Liu XS (2012) Differential DNase I hypersensitivity reveals factor-dependent chromatin dynamics. Genome Res 22(6):1015–1025. https://doi.org/10.1101/gr.133280.111 CrossRefPubMedPubMedCentral

85.

Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS, Keeton EK, Fertuck KC, Hall GF, Wang Q, Bekiranov S, Sementchenko V, Fox EA, Silver PA, Gingeras TR, Liu XS, Brown M (2006) Genome-wide analysis of estrogen receptor binding sites. Nat Genet 38(11):1289–1297. https://doi.org/10.1038/ng1901 CrossRefPubMed

86.

Lin CY, Vega VB, Thomsen JS, Zhang T, Kong SL, Xie M, Chiu KP, Lipovich L, Barnett DH, Stossi F, Yeo A, George J, Kuznetsov VA, Lee YK, Charn TH, Palanisamy N, Miller LD, Cheung E, Katzenellenbogen BS, Ruan Y, Bourque G, Wei CL, Liu ET (2007) Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet 3(6):e87. https://doi.org/10.1371/journal.pgen.0030087 CrossRefPubMedPubMedCentral

87.

Fullwood MJ, Liu MH, Pan YF, Liu J, Xu H, Mohamed YB, Orlov YL, Velkov S, Ho A, Mei PH, Chew EG, Huang PY, Welboren WJ, Han Y, Ooi HS, Ariyaratne PN, Vega VB, Luo Y, Tan PY, Choy PY, Wansa KD, Zhao B, Lim KS, Leow SC, Yow JS, Joseph R, Li H, Desai KV, Thomsen JS, Lee YK, Karuturi RK, Herve T, Bourque G, Stunnenberg HG, Ruan X, Cacheux-Rataboul V, Sung WK, Liu ET, Wei CL, Cheung E, Ruan Y (2009) An oestrogen-receptor-alpha-bound human chromatin interactome. Nature 462(7269):58–64. https://doi.org/10.1038/nature08497 CrossRefPubMedPubMedCentral

88.

Coons LA, Hewitt SC, Burkholder AB, McDonnell DP, Korach KS (2017) DNA sequence constraints define functionally active steroid nuclear receptor binding sites in chromatin. Endocrinology 158(10):3212–3234. https://doi.org/10.1210/en.2017-00468 CrossRefPubMedPubMedCentral

89.

Hah N, Murakami S, Nagari A, Danko CG, Kraus WL (2013) Enhancer transcripts mark active estrogen receptor binding sites. Genome Res 23(8):1210–1223. https://doi.org/10.1101/gr.152306.112 CrossRefPubMedPubMedCentral

90.

Carleton JB, Berrett KC, Gertz J (2017) Multiplex enhancer interference reveals collaborative control of gene regulation by estrogen receptor alpha-bound enhancers. Cell Syst 5:333–344.e5. https://doi.org/10.1016/j.cels.2017.08.011 CrossRefPubMedPubMedCentral

91.

Carleton JB, Berrett KC, Gertz J (2018) Dissection of enhancer function using multiplex CRISPR-based enhancer interference in cell lines. J Vis Exp. https://doi.org/10.3791/57883

92.

Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS (2011) FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet 43(1):27–33. https://doi.org/10.1038/ng.730 CrossRefPubMed

93.

Theodorou V, Stark R, Menon S, Carroll JS (2013) GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility. Genome Res 23(1):12–22. https://doi.org/10.1101/gr.139469.112 CrossRefPubMedPubMedCentral

94.

Metivier R, Penot G, Flouriot G, Pakdel F (2001) Synergism between ERalpha transactivation function 1 (AF-1) and AF-2 mediated by steroid receptor coactivator protein-1: requirement for the AF-1 alpha-helical core and for a direct interaction between the N- and C-terminal domains. Mol Endocrinol 15(11):1953–1970. https://doi.org/10.1210/mend.15.11.0727 CrossRefPubMed

95.

Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, Privalsky ML, Nakatani Y, Evans RM (1997) Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 90(3):569–580CrossRefPubMed

96.

Hong H, Kohli K, Trivedi A, Johnson DL, Stallcup MR (1996) GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. Proc Natl Acad Sci U S A 93(10):4948–4952CrossRefPubMedPubMedCentral

97.

Onate SA, Tsai SY, Tsai MJ, O'Malley BW (1995) Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270(5240):1354–1357CrossRefPubMed

98.

Chen JD, Evans RM (1995) A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377(6548):454–457. https://doi.org/10.1038/377454a0 CrossRefPubMed

99.

Horlein AJ, Naar AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, Ryan A, Kamei Y, Soderstrom M, Glass CK et al (1995) Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377(6548):397–404. https://doi.org/10.1038/377397a0 CrossRefPubMed

100.

Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M (2000) Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103(6):843–852CrossRefPubMed

101.

Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389(6652):753–758. https://doi.org/10.1038/39645 CrossRefPubMed

102.

Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86(7):527–537CrossRefPubMed

103.

Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL (1998) The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95(7):927–937CrossRefPubMed

104.

Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC (1988) Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 48(4):812–815PubMed

105.

Shang Y, Brown M (2002) Molecular determinants for the tissue specificity of SERMs. Science 295(5564):2465–2468. https://doi.org/10.1126/science.1068537 CrossRefPubMed

106.

Droog M, Nevedomskaya E, Dackus GM, Fles R, Kim Y, Hollema H, Mourits MJ, Nederlof PM, van Boven HH, Linn SC, van Leeuwen FE, Wessels LF, Zwart W (2017) Estrogen receptor alpha wields treatment-specific enhancers between morphologically similar endometrial tumors. Proc Natl Acad Sci U S A 114(8):E1316–E1E25. https://doi.org/10.1073/pnas.1615233114 CrossRefPubMedPubMedCentral

107.

Mohammed H, D'Santos C, Serandour AA, Ali HR, Brown GD, Atkins A, Rueda OM, Holmes KA, Theodorou V, Robinson JL, Zwart W, Saadi A, Ross-Innes CS, Chin SF, Menon S, Stingl J, Palmieri C, Caldas C, Carroll JS (2013) Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. Cell Rep 3(2):342–349. https://doi.org/10.1016/j.celrep.2013.01.010 CrossRefPubMedPubMedCentral

108.

Lobingier BT, Huttenhain R, Eichel K, Miller KB, Ting AY, von Zastrow M, Krogan NJ (2017) An approach to spatiotemporally resolve protein interaction networks in living cells. Cell 169(2):350–360 e12. https://doi.org/10.1016/j.cell.2017.03.022 CrossRefPubMedPubMedCentral

109.

Roux KJ, Kim DI, Burke B (2013) BioID: a screen for protein-protein interactions. Curr Protoc Protein Sci 74:Unit 19 23. https://doi.org/10.1002/0471140864.ps1923s74 CrossRef

110.

Sikora MJ (2016) Family matters: collaboration and conflict among the steroid receptors raises a need for group therapy. Endocrinology 157(12):4553–4560. https://doi.org/10.1210/en.2016-1778 CrossRefPubMedPubMedCentral

111.

Vahrenkamp JM, Yang CH, Rodriguez AC, Almomen A, Berrett KC, Trujillo AN, Guillen KP, Welm BE, Jarboe EA, Janat-Amsbury MM, Gertz J (2018) Clinical and genomic crosstalk between glucocorticoid receptor and estrogen receptor alpha in endometrial cancer. Cell Rep 22(11):2995–3005. https://doi.org/10.1016/j.celrep.2018.02.076 CrossRefPubMedPubMedCentral

112.

Prange-Kiel J, Rune GM, Zwirner M, Wallwiener D, Kiesel L (2001) Regulation of estrogen receptor alpha and progesterone receptor (isoform A and B) expression in cultured human endometrial cells. Exp Clin Endocrinol Diabetes 109(4):231–237. https://doi.org/10.1055/s-2001-15111 CrossRefPubMed

113.

Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA, Serandour AA, Birrell SN, Bruna A, Saadi A, Menon S, Hadfield J, Pugh M, Raj GV, Brown GD, D'Santos C, Robinson JL, Silva G, Launchbury R, Perou CM, Stingl J, Caldas C, Tilley WD, Carroll JS (2015) Progesterone receptor modulates ERalpha action in breast cancer. Nature 523(7560):313–317. https://doi.org/10.1038/nature14583 CrossRefPubMedPubMedCentral

114.

Singhal H, Greene ME, Tarulli G, Zarnke AL, Bourgo RJ, Laine M, Chang YF, Ma S, Dembo AG, Raj GV, Hickey TE, Tilley WD, Greene GL (2016) Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer. Sci Adv 2(6):e1501924. https://doi.org/10.1126/sciadv.1501924 CrossRefPubMedPubMedCentral

115.

Bever AT, Hisaw FL, Velardo JT (1956) Inhibitory action of desoxycorticosterone acetate, cortisone acetate, and testosterone on uterine growth induced by estradiol-17beta. Endocrinology 59(2):165–169. https://doi.org/10.1210/endo-59-2-165 CrossRefPubMed

116.

Bitman J, Cecil HC (1967) Differential inhibition by cortisol of estrogen-stimulated uterine responses. Endocrinology 80(3):423–429. https://doi.org/10.1210/endo-80-3-423 CrossRefPubMed

117.

Pan D, Kocherginsky M, Conzen SD (2011) Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer. Cancer Res 71(20):6360–6370. https://doi.org/10.1158/0008-5472.CAN-11-0362 CrossRefPubMedPubMedCentral

118.

Miranda TB, Voss TC, Sung MH, Baek S, John S, Hawkins M, Grontved L, Schiltz RL, Hager GL (2013) Reprogramming the chromatin landscape: interplay of the estrogen and glucocorticoid receptors at the genomic level. Cancer Res 73(16):5130–5139. https://doi.org/10.1158/0008-5472.CAN-13-0742 CrossRefPubMedPubMedCentral

119.

Pakdel F, Reese JC, Katzenellenbogen BS (1993) Identification of charged residues in an N-terminal portion of the hormone-binding domain of the human estrogen receptor important in transcriptional activity of the receptor. Mol Endocrinol 7(11):1408–1417. https://doi.org/10.1210/mend.7.11.8114756 CrossRefPubMed

120.

Weis KE, Ekena K, Thomas JA, Lazennec G, Katzenellenbogen BS (1996) Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Mol Endocrinol 10(11):1388–1398. https://doi.org/10.1210/mend.10.11.8923465 CrossRefPubMed

121.

Zhang QX, Borg A, Wolf DM, Oesterreich S, Fuqua SA (1997) An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res 57(7):1244–1249PubMed

122.

Toy W, Weir H, Razavi P, Lawson M, Goeppert AU, Mazzola AM, Smith A, Wilson J, Morrow C, Wong WL, De Stanchina E, Carlson KE, Martin TS, Uddin S, Li Z, Fanning S, Katzenellenbogen JA, Greene G, Baselga J, Chandarlapaty S (2017) Activating ESR1 mutations differentially affect the efficacy of ER antagonists. Cancer Discov 7(3):277–287. https://doi.org/10.1158/2159-8290.CD-15-1523 CrossRefPubMed

123.

Fanning SW, Mayne CG, Dharmarajan V, Carlson KE, Martin TA, Novick SJ, Toy W, Green B, Panchamukhi S, Katzenellenbogen BS, Tajkhorshid E, Griffin PR, Shen Y, Chandarlapaty S, Katzenellenbogen JA, Greene GL (2016) Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. Elife 5:e12792. https://doi.org/10.7554/eLife.12792 CrossRefPubMedPubMedCentral

124.

Fuqua SA, Gu G, Rechoum Y (2014) Estrogen receptor (ER) alpha mutations in breast cancer: hidden in plain sight. Breast Cancer Res Treat 144(1):11–19. https://doi.org/10.1007/s10549-014-2847-4 CrossRefPubMedPubMedCentral

125.

Jeselsohn R, Bergholz JS, Pun M, Cornwell M, Liu W, Nardone A, Xiao T, Li W, Qiu X, Buchwalter G, Feiglin A, Abell-Hart K, Fei T, Rao P, Long H, Kwiatkowski N, Zhang T, Gray N, Melchers D, Houtman R, Liu XS, Cohen O, Wagle N, Winer EP, Zhao J, Brown M (2018) Allele-specific chromatin recruitment and therapeutic vulnerabilities of ESR1 activating mutations. Cancer Cell 33(2):173–186 e5. https://doi.org/10.1016/j.ccell.2018.01.004 CrossRefPubMedPubMedCentral

126.

Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, Ferrer-Lozano J, Perez-Fidalgo JA, Cristofanilli M, Gomez H, Arteaga CL, Giltnane J, Balko JM, Cronin MT, Jarosz M, Sun J, Hawryluk M, Lipson D, Otto G, Ross JS, Dvir A, Soussan-Gutman L, Wolf I, Rubinek T, Gilmore L, Schnitt S, Come SE, Pusztai L, Stephens P, Brown M, Miller VA (2014) Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res : an official journal of the American Association for Cancer Research 20(7):1757–1767. https://doi.org/10.1158/1078-0432.CCR-13-2332 CrossRef

127.

Katzenellenbogen JA, Mayne CG, Katzenellenbogen BS, Greene GL, Chandarlapaty S (2018) Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance. Nat Rev Cancer 18(6):377–388. https://doi.org/10.1038/s41568-018-0001-z CrossRefPubMedPubMedCentral

128.

Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, Dvir A, Soussan-Gutman L, Jeselsohn R, Yelensky R, Brown M, Miller VA, Sarid D, Rizel S, Klein B, Rubinek T, Wolf I (2013) D538G mutation in estrogen receptor-alpha: a novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res 73(23):6856–6864. https://doi.org/10.1158/0008-5472.CAN-13-1197 CrossRefPubMed

129.

Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, Kalyana-Sundaram S, Wang R, Ning Y, Hodges L, Gursky A, Siddiqui J, Tomlins SA, Roychowdhury S, Pienta KJ, Kim SY, Roberts JS, Rae JM, Van Poznak CH, Hayes DF, Chugh R, Kunju LP, Talpaz M, Schott AF, Chinnaiyan AM (2013) Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 45(12):1446–1451. https://doi.org/10.1038/ng.2823 CrossRefPubMedPubMedCentral

130.

Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, Hudis C, Chen D, Taran T, Hortobagyi G, Greene G, Berger M, Baselga J, Chandarlapaty S (2013) ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 45(12):1439–1445. https://doi.org/10.1038/ng.2822 CrossRefPubMedPubMedCentral

131.

Zhao Y, Laws MJ, Guillen VS, Ziegler Y, Min J, Sharma A, Kim SH, Chu D, Park BH, Oesterreich S, Mao C, Shapiro DJ, Nettles KW, Katzenellenbogen JA, Katzenellenbogen BS (2017) Structurally novel antiestrogens elicit differential responses from constitutively active mutant estrogen receptors in breast cancer cells and tumors. Cancer Res 77(20):5602–5613. https://doi.org/10.1158/0008-5472.CAN-17-1265 CrossRefPubMedPubMedCentral

132.

Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, Akbani R, Bowlby R, Wong CK, Wiznerowicz M, Sanchez-Vega F, Robertson AG, Schneider BG, Lawrence MS, Noushmehr H, Malta TM, Stuart JM, Benz CC, Laird PW, Cancer Genome Atlas N (2018) Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell 173(2):291–304 e6. https://doi.org/10.1016/j.cell.2018.03.022 CrossRefPubMedPubMedCentral

133.

Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, He X, Liu S, Hoog J, Lu C, Ding L, Griffith OL, Miller C, Larson D, Fulton RS, Harrison M, Mooney T, JF MM, Luo J, Tao Y, Goncalves R, Schlosberg C, Hiken JF, Saied L, Sanchez C, Giuntoli T, Bumb C, Cooper C, Kitchens RT, Lin A, Phommaly C, Davies SR, Zhang J, Kavuri MS, McEachern D, Dong YY, Ma C, Pluard T, Naughton M, Bose R, Suresh R, McDowell R, Michel L, Aft R, Gillanders W, De Schryver K, Wilson RK, Wang S, Mills GB, Gonzalez-Angulo A, Edwards JR, Maher C, Perou CM, Mardis ER, Ellis MJ (2013) Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 4(6):1116–1130. https://doi.org/10.1016/j.celrep.2013.08.022 CrossRefPubMed

134.

Backes FJ, Walker CJ, Goodfellow PJ, Hade EM, Agarwal G, Mutch D, Cohn DE, Suarez AA (2016) Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer. Gynecol Oncol 141(2):312–317. https://doi.org/10.1016/j.ygyno.2016.03.006 CrossRefPubMedPubMedCentral

135.

Blanchard Z, Vahrenkamp JM, Berrett KC, Arnesen S, Gertz J (2018) Estrogen-independent molecular actions of mutant estrogen receptor alpha in endometrial cancer. bioRxiv. https://doi.org/10.1101/369165

136.

Bahreini A, Li Z, Wang P, Levine KM, Tasdemir N, Cao L, Weir HM, Puhalla SL, Davidson NE, Stern AM, Chu D, Park BH, Lee AV, Oesterreich S (2017) Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models. Breast Cancer Res : BCR 19(1):60. https://doi.org/10.1186/s13058-017-0851-4 CrossRefPubMedPubMedCentral

137.

Szwarc MM, Lydon JP, O'Malley BW (2015) Steroid receptor coactivators as therapeutic targets in the female reproductive system. J Steroid Biochem Mol Biol 154:32–38. https://doi.org/10.1016/j.jsbmb.2015.06.010 CrossRefPubMedPubMedCentral

138.

O'Hara AJ, Bell DW (2012) The genomics and genetics of endometrial cancer. Adv Genomics Genet 2012(2):33–47. https://doi.org/10.2147/AGG.S28953 CrossRefPubMedPubMedCentral

139.

Franco HL, Nagari A, Kraus WL (2015) TNFalpha signaling exposes latent estrogen receptor binding sites to alter the breast cancer cell transcriptome. Mol Cell 58(1):21–34. https://doi.org/10.1016/j.molcel.2015.02.001 CrossRefPubMedPubMedCentral

140.

Lupien M, Meyer CA, Bailey ST, Eeckhoute J, Cook J, Westerling T, Zhang X, Carroll JS, Rhodes DR, Liu XS, Brown M (2010) Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance. Genes Dev 24(19):2219–2227. https://doi.org/10.1101/gad.1944810 CrossRefPubMedPubMedCentral

141.

Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, Brown GD, Gojis O, Ellis IO, Green AR, Ali S, Chin SF, Palmieri C, Caldas C, Carroll JS (2012) Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481(7381):389–393. https://doi.org/10.1038/nature10730 CrossRefPubMedPubMedCentral

142.

Lortet-Tieulent J, Ferlay J, Bray F, Jemal A (2018) International patterns and trends in endometrial cancer incidence, 1978-2013. J Natl Cancer Inst 110(4):354–361. https://doi.org/10.1093/jnci/djx214 CrossRefPubMed

Title: Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions
Authors: Adriana C. Rodriguez
Zannel Blanchard
Kathryn A. Maurer
Jason Gertz
Publication date: 01-06-2019
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Endometrial Cancer
Endometrial Cancer
Estrogens
Progesterone
Progestin
Tamoxifen
Published in: Discover Oncology / Issue 2-3/2019
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-019-0358-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2-3/2019

Nuclear ErbB-2: a Novel Therapeutic Target in ErbB-2-Positive Breast Cancer?

Exploratory Analysis of Plasma Neurotensin as a Novel Biomarker for Early Detection of Colorectal Polyp and Cancer

The Combination of RET, BRAF and Demographic Data Identifies Subsets of Patients with Aggressive Papillary Thyroid Cancer

Recent Use of Oral Contraceptives and Risk of Luminal B, Triple-Negative, and HER2-Overexpressing Breast Cancer

Effects of Ketoconazole on ACTH-Producing and Non-ACTH-Producing Neuroendocrine Tumor Cells

Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page